Baird Financial Group, Inc. Castle Biosciences Inc Transaction History

Baird Financial Group, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$19.47 - $28.49 $14,388 - $21,054	-739 Reduced 6.06%	11,455 $260,000
Q3 2022 Nov 14, 2022	SELL	$22.51 - $34.32 $31,446 - $47,945	-1,397 Reduced 10.16%	12,349 $322,000
Q2 2022 Aug 08, 2022	SELL	$16.0 - $45.99 $9,648 - $27,731	-603 Reduced 4.2%	13,746 $302,000
Q1 2022 May 13, 2022	BUY	$33.17 - $46.98 $22,356 - $31,664	674 Added 4.93%	14,349 $644,000
Q4 2021 Feb 09, 2022	SELL	$39.06 - $67.58 $14,295 - $24,734	-366 Reduced 2.61%	13,675 $586,000
Q3 2021 Nov 12, 2021	BUY	$60.13 - $77.6 $87,068 - $112,364	1,448 Added 11.5%	14,041 $934,000
Q2 2021 Aug 11, 2021	BUY	$50.07 - $76.78 $11,516 - $17,659	230 Added 1.86%	12,593 $923,000
Q1 2021 May 13, 2021	BUY	$58.92 - $97.33 $46,370 - $76,598	787 Added 6.8%	12,363 $846,000
Q4 2020 Feb 11, 2021	BUY	$43.6 - $73.05 $82,142 - $137,626	1,884 Added 19.44%	11,576 $777,000
Q3 2020 Nov 12, 2020	BUY	$38.47 - $52.03 $372,851 - $504,274	9,692 New	9,692 $499,000

171

25.5M

511K

130K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $750M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Baird Financial Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Baird Financial Group, Inc. with notifications on news.